Aramark Reports Q1 Results, Maintains Strong FY26 Outlook Despite Calendar Shift Impact
summarizeSummary
Aramark reported mixed first-quarter fiscal 2026 results, with GAAP EPS declining and Adjusted EPS flat, but highlighted strong underlying performance and reaffirmed a positive full-year outlook for revenue, operating income, and adjusted EPS growth.
check_boxKey Events
-
Q1 Fiscal 2026 Results
Revenue increased 6% to $4.8 billion, with organic revenue up 5%. GAAP EPS decreased 8% to $0.36, while Adjusted EPS remained unchanged at $0.51.
-
Calendar Shift Impact
The company noted that a calendar shift negatively impacted Q1 results, estimating organic revenue growth would have been 8% and Adjusted EPS growth 13% without this effect, with a favorable impact expected in Q2.
-
Positive Full-Year Outlook Reaffirmed
Aramark reaffirmed its fiscal 2026 outlook, projecting organic revenue growth of 7-9%, Adjusted Operating Income growth of 12-17%, and Adjusted EPS growth of 20-25%.
-
Capital Allocation Initiatives
The company repurchased $30 million of common stock and favorably repriced $2.4 billion in term loans, reducing annual interest expense.
auto_awesomeAnalysis
Aramark's first-quarter results present a nuanced picture, with reported GAAP EPS declining and Adjusted EPS flat. However, the company provided crucial context regarding a calendar shift that significantly impacted these figures, indicating a much stronger underlying operational performance. The reaffirmation of a robust full-year fiscal 2026 outlook, projecting substantial growth in revenue, operating income, and adjusted EPS, is a key positive takeaway. Additionally, proactive capital management through share repurchases and debt repricing demonstrates financial discipline. Investors will likely focus on the strong forward guidance and the expected rebound in Q2 as the calendar shift reverses its impact.
At the time of this filing, ARMK was trading at $40.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $29.92 to $44.49. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.